Korean Circ J.  2024 May;54(5):268-269. 10.4070/kcj.2024.0099.

The Intertwined Relationship Between Heart Failure and Atrial Fibrillation, How Can We Untangle It?

• Heo R

• KMID: 2556523
• DOI: http://doi.org/10.4070/kcj.2024.0099

Reference

1. Park SM, Lee SY, Jung MH, et al. Korean Society of Heart Failure guidelines for the management of heart failure: management of the underlying etiologies and comorbidities of heart failure. Korean Circ J. 2023; 53:425–451. PMID: 37525389.

2. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Korean Circ J. 2023; 53:217–238. PMID: 37161681.

3. Batul SA, Gopinathannair R. Atrial fibrillation in heart failure: a therapeutic challenge of our times. Korean Circ J. 2017; 47:644–662. PMID: 28955382.

4. Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS One. 2021; 16:e0244689. PMID: 33606705.

5. Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018; 25:495–502. PMID: 29372664.

6. Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021; 18:1098–1105. PMID: 33757845.

7. Kim M, Ha KH, Lee J, et al. Lower atrial fibrillation risk with sodium-glucose cotransporter 2 inhibitors than with dipeptidyl peptidase-4 inhibitors in individuals with type 2 diabetes: a nationwide cohort study. Korean Circ J. 2024; 54:256–267. PMID: 38654455.

8. Ling AW, Chan CC, Chen SW, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020; 19:188. PMID: 33158436.

9. Lee S, Zhou J, Leung KS, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2023; 37:561–569. PMID: 35142921.

10. Norhammar A, Bodegård J, Nyström T, Thuresson M, Nathanson D, Eriksson JW. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study. Diabetes Obes Metab. 2019; 21:1136–1145. PMID: 30609272.

11. Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018; 20:344–351. PMID: 28771923.